ArticleDEN open2025
Comparison of remimazolam and midazolam for sedation during colonoscopy in Japanese patients: A propensity score matching analysis.
Article in DEN open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Efficacy and recovery of remimazolam versus midazolam in sedated upper gastrointestinal endoscopy: a multicenter randomized controlled trial in Japan (RECOVER Study).Journal of gastroenterology · 2026Trial
- Efficacy and Recovery of Remimazolam Versus Midazolam in Sedated Colonoscopy: A Multicenter Randomized Controlled Trial in Japan.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Trial
- Update on Sedation for Upper Gastrointestinal Endoscopy in Japan: Current Evidence on Remimazolam.DEN open · 2027Review
- Comparison of Remimazolam and Midazolam for Sedation During Endoscopic Retrograde Cholangiopancreatography-Related Procedures.DEN open · 2026Article
- Article
- Sedation with remimazolam besylate versus midazolam in acute respiratory distress syndrome patients supported by venovenous extracorporeal membrane oxygenation: a study protocol for a multicenter prospective randomized trial.Journal of thoracic disease · 2026Article
- Real-World Evaluation of Remimazolam for Sedation During Gastrointestinal Endoscopy: Efficacy, Safety, and Risk Factors.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Usefulness and safety of remimazolam in upper gastrointestinal endoscopy: A comparative study between elderly and non-elderly patients.DEN open · 2025Article
- Hemodynamic Stability of Midazolam versus Remimazolam During Outpatient Genitourinary Interventional Radiology Procedures in a Patient With Aortic Stenosis: A Case Report.A&A practice · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare the efficacy and safety of sedation with midazolam and remimazolam for colorectal endoscopy. Methods: This single-center, two-arm, post-hoc analysis of the REM-IICTJP01 study investigated the efficacy and safety of remimazolam for gastrointestinal endoscopic sedation. We enrolled 40 and 208 patients who underwent colonoscopy under remimazolam and midazolam sedation, respectively, during the same period. The primary outcome was the time from the end of the colonoscopy until discharge. The secondary outcomes included the time from the end of the colonoscopy until awakening, dosage, and adverse events. Propensity score matching was employed to eliminate the effect of confounding factors. Results: Thirty-seven patients in each group were matched. After propensity matching, the time to awakening after colonoscopy was 28.0 (13.0-37.0) min in the midazolam group and 0 (0-0) min in the remimazolam group; moreover, the time till discharge was 40.0 (35.0-46.5) min in the midazolam group and 0 (0-5.0) min in the remimazolam group, both of which were significantly shorter in the remimazolam group ( Conclusions: Remimazolam yielded significantly faster times to awakening and discharge safely compared to midazolam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.